Polycythemia vera: Difference between revisions
Jump to navigation
Jump to search
imported>Thomas E Kelly No edit summary |
imported>Aleksander Stos (cleanup) |
||
| Line 2: | Line 2: | ||
== JAK2 mutations == | == JAK2 mutations == | ||
Mutations in the JAK2 gene, specifically at the V617F locus, give rise to [[myeloproliferative syndromes|myeloproliferative disorders]] such as [[essential thrombocythemia]] and [[polycythemia vera]].<ref>Scott, et al. New Engl J Med 356: 459-468 2007.</ref> | |||
Authors <ref> | Authors reported<ref>James, et al. Nature 434:1144-8 2005.</ref> that other mutations of the coding region of the JAK2 gene could create a polycythemia phenotype. | ||
==References== | |||
< | <references/> | ||
[[Category: Health Sciences Workgroup]] | |||
[[Category: CZ Live]] | [[Category: CZ Live]] | ||
Revision as of 16:28, 22 March 2007
Clinical criteria
JAK2 mutations
Mutations in the JAK2 gene, specifically at the V617F locus, give rise to myeloproliferative disorders such as essential thrombocythemia and polycythemia vera.[1]
Authors reported[2] that other mutations of the coding region of the JAK2 gene could create a polycythemia phenotype.